Investigational drug · Phase 3
GS-3242
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV-1-infection, HIV-1 Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "GS-3242"
First trial start
2026
Jun 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GS-3242", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1-infection
- HIV-1 Infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "GS-3242" as an intervention, largest first.
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07708727 · 700 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2030
Drug: GS-3242 Tablet; GS-3242 Injection and 3 more · For: HIV-1-infection
Sites: Torrance, California; New Haven, Connecticut; Ft. Pierce, Florida · 21 sites in all
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Pivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07645287 · 175 participants (planned) · Start Jun 15, 2026 · Primary completion Aug 2027
Drug: GS-3242 Tablet; GS-3242 Injection and 3 more · For: HIV-1-infection
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 59 sites in all
- Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07841990 · 125 participants (planned) · Start Oct 1, 2026 · Primary completion Aug 2027
Drug: B/F/TAF; GS-3242 and 1 more · For: HIV-1 Infection
Sites: Ft. Pierce, Florida; Houston, Texas
Gilead SciencesGilead Sciences (GILD)
NCT07001319 · 27 participants · Start May 29, 2025 · Primary completion Mar 3, 2026
Drug: GS-3242; BVY and 1 more · For: HIV-1-infection
Sites: Bakersfield, California; Los Angeles, California; San Francisco, California · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HIV-1-infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- OBRPhase 32 trials
Gilead Sciences · HIV-1-infection
- TMB-365TMB-380, VRC07523LSPhase 23 trials
TaiMed Biologics Inc. · HIV-1-infection, HIV -1 Infection
- CAP256V2LSPhase 21 trial
Gilead Sciences · HIV-1-infection
- PirmitegravirPhase 21 trial
ST Pharm Co., Ltd. · HIV-1-infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.